Nektar Therapeutics NKTR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$158.1M+3.6% | -$164.08M-28.2% | -$128M+1.2% | -$129.53M+7.7% | -$140.3M-11.2% | ||
| $751K-26.8% | $1.03M-12.2% | $1.17M-40.6% | $1.97M-38.8% | $3.21M-26.9% | ||
| $12.11M-4.3% | $12.65M-17.1% | $15.26M-13.2% | $17.58M-9.9% | $19.51M-9.7% | ||
| -$203.76M+2.3% | -$208.51M-9.9% | -$189.74M-2.6% | -$184.91M-4.5% | -$176.87M-0.7% | ||
| $187K+9.4% | $171K-72.1% | $612K-47.4% | $1.16M-11.3% | $1.31M-10.6% | ||
| —— | —— | $58.65M-70.6% | $199.63M+19.5% | $167M+17.1% | ||
| $710.11M+293% | $180.57M+27.2% | $141.98M+45,116% | $314K+157% | $122K-99.7% | ||
| —— | —— | —— | —— | -$9.75M-209% | ||
| -$203.94M+2.3% | -$208.68M-9.6% | -$190.35M-2.3% | -$186.07M-4.4% | -$178.19M-0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.